CoronaryAtlas logo
CoronaryAtlas
PPARG
Pathway / Lipid retention & oxidation

PPARG

PPARGgene

PPARG promotes reverse cholesterol transport and resolves post-MI inflammation, opposing atherosclerotic lipid accumulation.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationalePPAR-γ mediates reverse cholesterol transport and anti-inflammatory lipid metabolism.
Also acts inVascular inflammation
Druggability
DruggableYes
Known drugs / candidates40
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000132170

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
41
C — confounder / Type-II
70
A — assay feasibility
52
E — evidence strength
26
T1DI (composite)
5
Specificity differential (R−C)-29.1
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable

Literature evidence(6)